HCM
ANAB icon

Hollencrest Capital Management’s AnaptysBio ANAB Stock Holding History

Hollencrest Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.38K Hold
50
– – ﹤0.01% 964
2026
Q1 		$2.77K Buy
+50
New +$2.69K ﹤0.01% 991

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Hollencrest Capital Management's ANAB Position: Q2 2026 in Review

Hollencrest Capital Management held its AnaptysBio (ANAB) position steady in Q2 2026 at 50 shares worth $3.38K. The position accounts for ﹤0.01% of the portfolio, ranked #964.

Hollencrest Capital Management first reported a position in ANAB in Q1 2026 and has held it in 2 quarters since. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Hollencrest Capital Management held 50 shares of AnaptysBio worth $3.38K as of Q2 2026.
  • Hollencrest Capital Management left its AnaptysBio share count unchanged in Q2 2026.
  • AnaptysBio made up ﹤0.01% of Hollencrest Capital Management's portfolio in Q2 2026, its #964 holding.
  • Hollencrest Capital Management first reported a position in AnaptysBio in Q1 2026 and has held it in 2 quarters since.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.